In Europe, Gilead flags CAR T access challenges

A new report highlights disparities in access to CAR T-cell therapies across Europe, with eligible patient treatment rates as low as 11% in some countries. The analysis suggests that complex care pathways and inconsistent funding models are key barriers to broader use of the treatment.

The report was developed by the IQVIA Institute for Human Data Science, with funding from US pharma major and CAR T developer Gilead Sciences (Nasdaq: GILD).

CAR T-cell therapies are personalized cancer treatments used primarily for aggressive blood cancers. Their use has been growing since first becoming available in 2017, but the treatment’s complexity requires coordination among multiple specialists, hospital departments, and national regulators.